U.S. Sen. Kelly Loeffler (R-GA) welcomes a crowd during a runoff election night party at Grand Hyatt Hotel in Buckhead on January 6, 2021 in Atlanta, Georgia. (Photo by Brandon Bell/Getty Images) ATLANTA - President-elect Donald Trump announced on Wednesday that he will nominate former U.S. Senator Kelly Loeffler to serve as the head of the Small Business Administration (SBA) in his upcoming administration. In a post on his social media platform, Truth Social, Trump praised Loeffler’s extensive experience in business and government. He emphasized her skills in streamlining operations and fostering growth for small businesses, which he described as 'the backbone of our great economy.' "Kelly will bring her experience in business and Washington to reduce red tape, and unleash opportunity for our Small Businesses to grow, innovate, and thrive," Trump wrote. "She will focus on ensuring that SBA is accountable to Taxpayers by cracking down on waste, fraud, and regulatory overreach." Georgia Gov. Brian Kemp appointed Loeffler to the U.S. Senate in December 2019 after Sen. Johnny Isakson resigned due to health issues. She served until January 2021 but was defeated in a special election by Democrat Raphael Warnock in a January 2021 runoff. Trump commended her work on legislation aimed at protecting women in sports. Prior to her political career, Loeffler spent 25 years in financial services and technology. As Executive Vice President, she contributed to the growth of a company that expanded from 100 employees to over 10,000 and achieved Fortune 500 status. "Kelly was a tremendous fighter in the U.S. Senate," Trump said. "Along with her amazing husband, Jeff, she helped build a Fortune 500 company and played a crucial role in securing my Big Election Win in Georgia." Upon confirmation, Loeffler would oversee the agency tasked with aiding, counseling, assisting, and protecting the interests of small business concerns and helping families and businesses recover from national and other declared disasters. A native of Illinois, Loeffler moved to Georgia in the early 2000s and quickly rose to prominence in the state's business and political scenes. She and her husband, Jeffrey Sprecher, co-own the Atlanta Dream, a WNBA team, and have been active Republican donors. Loeffler is currently a co-chair of Trump's inaugural committee. The Source: The naming of former Sen. Kelly Loeffler was announced by President-elect Donald Trump on his social media platform Truth Social. Details about Loeffler's life and career were compiled using previous reports by FOX 5 Atlanta, the Associated Press, and FOX News.
Surv Essex: Transforming Property Dreams Across Essex with Expert Architectural, Surveying, and Party Wall ServicesNEWCASTLE, England (AP) — Newcastle’s winning run in the English Premier League came to an abrupt end when goals from Thomas Souček and Aaron Wan-Bissaka gave West Ham a surprise 2-0 win at St. James’ Park on Monday. The Hammers rose into 14th place and the pressure on coach Julen Lopetegui was eased. The London club has been inconsistent all season and Monday’s win was just its fourth in 12 league games. West Ham was worth the win in the end but the three points came courtesy of slack defending by the home side. Emerson whipped in an out-swinging corner after 10 minutes and, with Newcastle defenders rooted to the spot, Souček stole in to nod home the opener. Then eight minutes into the second half, captain Jarrod Bowen found Wan-Bissaka in the penalty box and he was left unchallenged and had time to fire an angled drive past Nick Pope. Newcastle brought on Harvey Barnes, and then Callum Wilson returned from a long-term back injury to make his first appearance of the season but to no avail. The defeat ended a three-game winning streak for Newcastle and left the Saudi Arabia-owned club in ninth place, four points outside the top four. AP soccer: https://apnews.com/hub/soccer
Grande, 31, also said her co-star was a “brilliant gift of a human being” while being interviewed by Gladiator star Paul Mescal for US news outlet Variety. Mescal told the singer and actor: “I’m watching you guys in the press tour. You’re obviously in love with each other.” To which she replied: “Insufferable. Yes. We’re horrible. It’s bad.” The 7 Rings singer plays Glinda, while her 37-year-old co-star plays Elphaba, in the film which is an adaption of the musical stage show of the same name and is set in The Land Of Oz before the events of The Wizard Of Oz. Their interviews for the film, which have seen the two being emotional towards one another and holding hands, have gone viral on social media. Speaking about Erivo, Grande said: “Cynthia is just an absolute brilliant gift of a human being. I think we tried to keep the pressure out of the room, obviously, as much as possible.” She also said she had not had any read throughs with her co-star before joining the cast. Grande said: “We never chemistry read together, it was three rounds for me, and I read with two different actresses. “I stayed for three and a half hours the final day, and I had cried so much. “We did Popular, Defying Gravity, (and) For Good (songs from the film), and I left my lashes on the mirror, because I left everything else in the room.” The film follows Elphaba, who is misunderstood because of her green skin, as she forges an unlikely friendship with Glinda, a student with a desire for popularity. Bullying of the green-skinned witch saw the movie, which also stars Peter Dinklage, Jeff Goldblum and Jonathan Bailey, given a PG rating by the British Board Of Film Classification (BBFC) for “discrimination”.Joe Burrow is no longer talking about the playoffs after another loss by the high-scoring Bengals
Large UN Aid Convoy 'Violently Looted' After Entering Gaza - Somehow Israel Is Being BlamedNoneNone
Prosecutor makes decision in Jameson Williams gun caseJoe Biden Aggressively Fights For Trump, Handing Him Victories Left And RightUVM looks to transition dialysis care to new provider; 40 patients affected in St. Albans
Romanian constitutional court validates first round of presidential race after vote recount
None
TORONTO — Hannah Miller scored a power-play goal with 1:38 remaining in the game, lifting the Toronto Sceptres to a 3-1 victory over the Boston Fleet in the Professional Women's Hockey League season opener on Saturday. With Boston standout Hilary Knight in the penalty box for a vicious boarding penalty on Sceptres defender Renata Fast, Miller made good on her rebound attempt on a Daryl Watts shot with a half-open net. Fast recovered for an assist on the winner before 8,089 fans at Coca-Cola Coliseum. The Fleet (0-1-0) challenged the goal, but video review deemed Miller's shot was good. Sarah Nurse got Toronto (1-0-0) on the board with a short-handed tally 11:50 into the first period and Emma Maltais added an empty-net strike to seal the score at 3-1 with 12 seconds left on the game clock. Boston's Hilary Knight opened the scoring at the 3:00 mark of the opening frame, sending a slap shot past Toronto goalie Kristin Campbell, who registered 18 stops on the night. Toronto outshot Boston 41-19. Boston goalie Aerin Frankel, a big reason why her team advanced to the Walter Cup final last spring, was outstanding with 38 saves. Frankel made a significant glove-hand stop on Toronto defender Jocelyne Larocque with 6:36 remaining in the third period. Larocque was alone when a rebound caromed to her in front. But the puck was rolling, and she could only lift her shot straight into Frankel's glove. Nurse's goal tested the league's new jailbreak rule that sees a minor penalty — in this case, Izzy Daniel's tripping infraction — wiped out when a team scores a short-handed goal. . Takeaways Sceptres: Billie Jean King MVP Natalie Spooner missed the season opener. The PWHL scoring champion underwent left knee surgery last June after getting injured in Game 3 of Toronto's first-round series against Minnesota. Fleet: Defender Emma Greco of Burlington, Ont., played her first game for Boston. She was part of the Walter Cup-winning Minnesota team that defeated Boston in a three-game series last spring. Greco is one of five Ontario-born players on the Fleet roster. Key moment With the game tied 1-1, the Sceptres failed to score during a 59-second 5-on-3 advantage midway through the second period. Boston blocked five shots during the span. Key stat Last year, Toronto enjoyed an 11-game win streak en route to its regular-season championship, including three wins against Boston. Up next Toronto visits Ottawa on Tuesday. Boston will play its home opener on Wednesday, a rematch with the Walter Cup-champion Minnesota. This report by The Canadian Press was first published Nov. 30, 2024. Tim Wharnsby, The Canadian Press
US stocks rose Monday, with the Dow finishing at a fresh record as markets greeted Donald Trump's pick for treasury secretary, while oil prices retreated on hopes for a ceasefire between Israel and Hezbollah. The Dow climbed one percent to a second straight all-time closing high on news of the selection of hedge fund manager Scott Bessent to lead the critical economic policy position. A widely respected figure on Wall Street, Bessent is seen as being in favor of growth and deficit reduction policies and not known overly fond of trade tariffs. The market "breathed a sigh of relief" at Bessent's selection, said Art Hogan from B. Riley Wealth Management. But after an initial surge Monday, the gains in US equities moderated somewhat. While investors are enthusiastic about the possibility of tax cuts and regulatory relief under Trump, "we do have to face the potential for tariffs being a negative as well as a very tight market around immigration, which is not positive for the economy," Hogan said. Earlier, equity gains were limited in Europe as growth concerns returned to the fore with Germany's Thyssenkrupp announcing plans to cut or outsource 11,000 jobs in its languishing steel division. Currently around 27,000 people are employed in the steel division, which has been battered by high production costs and fierce competition from Asian rivals. Elsewhere, crude oil prices fell decisively as Israel's security cabinet prepared to decide whether to accept a ceasefire in its war with Hezbollah, an official said Monday. The United States, the European Union and the United Nations have all pushed in recent days for a truce in the long-running hostilities between Israel and Hezbollah, which flared into all-out war in late September. Speaking on condition of anonymity, an Israeli official told AFP the security cabinet "will decide on Tuesday evening on the ceasefire deal." And bitcoin's push toward $100,000 ran out of steam after coming within a whisker of the mark last week, on hopes that Trump would enact policies to bring the cryptocurrency more into the mainstream. Bitcoin was recently trading under $96,000, having set a record high of $99,728.34 Friday -- the digital currency has soared about 50 percent in value since Trump's election. This week's data includes a reading of consumer confidence and an update of personal consumption prices, a key inflation indicator. Those reporting earnings include Best Buy, Dell and Dick's Sporting Goods. New York - Dow: UP 1.0 percent at 44,736.57 (close) New York - S&P 500: UP 0.3 percent at 5,987.37 (close) New York - Nasdaq: UP 0.3 percent at 19,054.84 (close) London - FTSE 100: UP 0.4 percent at 8,291.68 (close) Paris - CAC 40: FLAT at 7,257.47 (close) Frankfurt - DAX: UP 0.4 percent at 19,405.20 (close) Tokyo - Nikkei 225: UP 1.3 percent at 38,780.14 (close) Hong Kong - Hang Seng Index: DOWN 0.4 percent at 19,150.99 (close) Shanghai - Composite: DOWN 0.1 percent at 3,263.76 (close) Euro/dollar: UP at $1.0495 from $1.0418 on Friday Pound/dollar: UP at $1.2564 from $1.2530 Dollar/yen: DOWN at 154.23 yen from 154.78 yen Euro/pound: UP at 83.51 pence from 83.14 pence West Texas Intermediate: DOWN 3.2 percent at $68.94 per barrel Brent North Sea Crude: DOWN 2.9 percent at $73.01 per barrel bur-jmb/dw
LAUSANNE, Switzerland -- Russian billionaire Alisher Usmanov has been elected to a new term as president of the International Fencing Federation while he faces ongoing sanctions. The federation, known as the FIE, said in an emailed statement that Usmanov won 120 votes for a majority at the congress on Saturday in Uzbekistan, where he was born. Usmanov was first elected FIE president in 2008 and his funding was key to fencing's growth. Usmanov said in March 2022 he would step aside from his duties as FIE president “until justice is restored” after he was placed under sanctions by the European Union following the Russian invasion of Ukraine. Greek official Emmanuel Katsiadakis served as interim president since then. Usmanov thanked his supporters on Saturday and said he would work for a “bright future” for fencing. “As is well known, I am still subject to unjustified restrictions, which I am currently challenging in court," Usmanov said in a statement. "In this regard, I declare that I have always acted in the best interests of the FIE and will continue to take all necessary measures to prevent the legally unfounded restrictions imposed on me being extended to the FIE and its activities.” ___ AP sports: https://apnews.com/hub/sportsTHOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE Amgen
Mario Andretti reacts to being named to board of directors of new Cadillac F1 teamSalamanca football punches ticket to NYS title game for first time in 25 years'Dummy': Trump's fiery spokesman lashes out at reporter with profane postFalcons vs. Chargers Predictions & Picks: Odds, Moneyline, Spread – Week 13
None